NCLifeSci Blog

Recipients of inaugural Samuel Taylor Life Sciences Scholarships named

NCBIO and the N.C. Community College System announced the recipients of the newly established Samuel M. Taylor Memorial Life Sciences Scholarship. The Samuel M. Taylor Scholarship was established at the North Carolina Community Colleges Foundation Inc. in memory of Sam Taylor, a founder and... Continue Reading

BIO: What happened with the Orphan Drug Tax Credit

During a busy week in Congress, Democrats included a change to the Orphan Drug Tax Credit that would negatively impact research on rare diseases affecting millions of Americans. The U.S. House of Representatives has several committees marking up the Senate’s $3.5 trillion budget... Continue Reading

BIO’s fall Congressional preview

The summer calm is grinding to a halt as members of Congress have returned to D.C. for what is sure to be a busy legislative sprint that could potentially impact all sectors of the biotech industry. The State of Play The House adjourned two weeks ago after laying the groundwork (on a party-line... Continue Reading

Life Science Caucus focuses on supporting innovative agricultural tech

Rep. Donna McDowell White welcomes attendees NCBIO President Laura Gunter Scott Uknes, Ph.D., co-founder and co-CEO of AgBiome John Fleming, a farmer and partner with Fleming Brothers Farms, LLC in Halifax Sinnovatek President and CEO Michael Druga T. Y. Baker and... Continue Reading

NC Commerce Secretary Sanders lays out state’s First in Talent plan at BMF meeting

NC Secretary of Commerce Machelle Sanders North Carolina Secretary of Commerce Machelle Baker Sanders encouraged the life sciences industry to be an active participant in shaping the state’s economic plan during the quarterly meeting of the NCBIO Biotech Manufacturer’s Forum held... Continue Reading

BIO: Where things stand with TRIPS waiver

BIO: Where things stand with TRIPS waiver It’s been a while since we’ve talked about what’s going on at the WTO. Here’s the latest news—and why the proposed waiver of vaccine IP is still a bad idea. The status: The World Trade Organization is still... Continue Reading

NCBIO members inform state legislators at July Life Science Caucus meeting

Representatives from G1 Therapeutics, United Therapeutics and Thermo Fisher Scientific shared insights from their companies with members of the North Carolina General Assembly's Life Science Caucus on during its meeting held Wednesday, July 21. Caucus co-chairs Sen. Mike Woodard, Sen.... Continue Reading

NCBIO forum offers guidance on creating new lab space

When it comes to creating lab space for a new or established business, getting your team together early and allowing plenty of time to plan are the keys to success, according to panelists assembled for NCBIO’s Lab Space Forum held online Tuesday, July 13. The pandemic has caused... Continue Reading

Laura Gunter named new NCBIO president

Laura Gunter Laura Gunter, M.B.A, has been selected as the new president of NCBIO, the N.C. Biosciences Organization, succeeding longtime president Sam Taylor who died in February. Gunter has served as the organization’s executive vice president since 2020 and has filled the executive... Continue Reading

BIO: How the PASTEUR Act would support antibiotic R&D

BIO: How the PASTEUR Act would support antibiotic R&D The PASTEUR Act, legislation designed to make research and development of new antibiotics economically viable, was reintroduced in Congress last week with bipartisan support. Here’s what it would do and why it... Continue Reading

Government price fixing for U.S. medicines will cost lives, jobs, innovation

Government price fixing for U.S. medicines will cost lives, jobs, innovation Legislation that fixes prices for prescription medicines would limit patients’ access to new treatments while doing nothing to lower prices at the pharmacy counter, according to a new analysis released by... Continue Reading

Vaccine patent waiver breaks faith with American companies, stifles innovation

Vaccine patent waiver breaks faith with American companies, stifles innovation NCBIO is extremely disappointed that the Biden administration has chosen to support waiving critical intellectual property protections for U.S. COVID-19 vaccines. This decision, known as a TRIPS waiver,... Continue Reading